|
1
|
Ménard S, Casalini P, Campiglio M, Pupa SM
and Tagliabue E: Role of HER2/neu in tumor progression and therapy.
Cell Mol Life Sci. 61:2965–2978. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kim KC, Koh YW, Chang HM, Kim TH, Yook JH,
Kim BS, Jang SJ and Park YS: Evaluation of HER2 protein expression
in gastric carcinomas: Comparative analysis of 1,414 cases of
whole-tissue sections and 595 cases of tissue microarrays. Ann Surg
Oncol. 18:2833–2840. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jørgensen JT: Role of human epidermal
growth factor receptor 2 in gastric cancer: Biological and
pharmacological aspects. World J Gastroenterol. 20:4526–4535. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Olayioye MA: Update on HER-2 as a target
for cancer therapy: Intracellular signaling pathways of ErbB2/HER-2
and family members. Breast Cancer Res. 3:385–389. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Olayioye MA, Graus-Porta D, Beerli RR,
Rohrer J, Gay B and Hynes NE: ErbB-1 and ErbB-2 acquire distinct
signaling properties dependent upon their dimerization partner. Mol
Cell Biol. 18:5042–5051. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Roy V and Perez EA: Beyond trastuzumab:
Small molecule tyrosine kinase inhibitors in HER-2-positive breast
cancer. Oncologist. 14:1061–1069. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu Y, Chen Y, Qu R, Lan T and Sang J: Type
II cGMP-dependent protein kinase inhibits EGF-triggered signal
transduction of the MAPK/ERK-mediated pathway in gastric cancer
cells. Oncol Rep. 27:553–558. 2012.
|
|
8
|
Lan T, Chen Y, Sang J, Wu Y, Wang Y, Jiang
L and Tao Y: Type II cGMP-dependent protein kinase inhibits
EGF-induced MAPK/JNK signal transduction in breast cancer cells.
Oncol Rep. 27:2039–2044. 2012.PubMed/NCBI
|
|
9
|
Taniyama K, Ishida K, Toda T, Motoshita J,
Kuraoka K, Saito A, Tani Y, Uike T, Teramoto S and Koseki M:
Tyrosine1248-phosphorylated HER2 expression and HER2 gene
amplification in female invasive ductal carcinomas. Breast Cancer.
15:231–240. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jiang L, Lan T, Chen Y, Sang J, Li Y, Wu
M, Tao Y, Wang Y, Qian H and Gu L: PKG II inhibits EGF/EGFR-induced
migration of gastric cancer cells. PLoS One. 8:e616742013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ferro A, Peleteiro B, Malvezzi M, Bosetti
C, Bertuccio P, Levi F, Negri E, La Vecchia C and Lunet N:
Worldwide trends in gastric cancer mortality (1980–2011), with
predictions to 2015 and incidence by subtype. Eur J Cancer.
50:1330–1344. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hynes NE and MacDonald G: ErbB receptors
and signaling pathways in cancer. Curr Opin Cell Biol. 21:177–184.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Olayioye MA, Neve RM, Lane HA and Hynes
NE: The ErbB signaling network: Receptor heterodimerization in
development and cancer. Embo J. 19:3159–3167. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Birtwistle MR, Hatakeyama M, Yumoto N,
Ogunnaike BA, Hoek JB and Kholodenko BN: Ligand-dependent responses
of the ErbB signaling network: Experimental and modeling analyses.
Mol Syst Biol. 3:1442007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gulliford T, Ouyang X and Epstein RJ:
Intensification of growth factor receptor signalling by phorbol
treatment of ligand-primed cells implies a dimerstabilizing effect
of protein kinase C-dependent juxtamembrane domain phosphorylation.
Cell Signal. 11:245–252. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Monje PV, Athauda G and Wood PM: Protein
kinase A-mediated gating of neuregulin-dependent ErbB2-ErbB3
activation underlies the synergistic action of cAMP on Schwann cell
proliferation. J Biol Chem. 283:34087–34100. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fink BE, Norris D, Mastalerz H, Chen P,
Goyal B, Zhao Y, Kim SH, Vite GD, Lee FY, Zhang H, et al: Novel
pyrrolo[2,1-f] [1,2,4] triazin-4-amines: Dual inhibitors of EGFR
and HER2 protein tyrosine kinases. Bioorg Med Chem Lett.
21:781–785. 2011. View Article : Google Scholar
|
|
18
|
Xia W, Mullin RJ, Keith BR, Liu LH, Ma H,
Rusnak DW, Owens G, Alligood KJ and Spector NL: Anti-tumor activity
of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation
of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene.
21:6255–6263. 2002. View Article : Google Scholar : PubMed/NCBI
|
